Brief: TC Biopharm Announces Positive Phase 1B/2A Data In Late-Stage Acute Myeloid Leukemia Patients
08/03/2022 13:36
March 8 (Reuters) - TC BioPharm Ltd T0Uy.F :
* TC BIOPHARM ANNOUNCES POSITIVE PHASE 1B/2A DATA IN LATE-STAGE ACUTE
MYELOID
LEUKEMIA PATIENTS TREATED WITH ALLOGENEIC GAMMA DELTA T CELLS
* TC BIOPHARM - DURING 2022 PLAN TO EVALUATE OMNIMMUNE EFFICACY IN
UNRESPONSIVE
FIRST-LINE OF TREATMENT AML PATIENTS
* TC BIOPHARM - LOOK FORWARD TO REPORTING ADDITIONAL PHASE 2/3 CLINICAL
DATA FROM
OMNIMMUNE DURING FIRST HALF OF 2022
Source text for Eikon: ID:nPnbC9K8Ya
Further company coverage: T0Uy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TC Biopharm (Holdings)
See all newsBrief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: TC BioPharm Announces Complete Response In Minimal Residual Disease Patient
Brief: TCBP Announces Non-Binding Letter Of Intent To Acquire Commercial Stage Ophthalmic Pharmaceutical Company
Brief: TC Biopharm's Data Show A Favorable Response In Patients With Relapse Or Refractory AML
Brief: TCBP Trading Continues Unabated On Nasdaq Stock Exchange